ASP1585 + Placebo + Sevelamer hydrochloride
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Trial Timeline
Oct 1, 2007 → Sep 1, 2008
NCT ID
NCT00505037About ASP1585 + Placebo + Sevelamer hydrochloride
ASP1585 + Placebo + Sevelamer hydrochloride is a phase 2 stage product being developed by Astellas Pharma for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00505037. Target conditions include Hyperphosphatemia, Chronic Kidney Disease.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00505037 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia